News and Events

R3 Seminar Recap: RECOVER Observational Studies Consortium: Where we are and where we are headed

During the January 23rd RECOVER Research Review (R3) Seminar, researchers presented on the progress and future directions of the RECOVER Initiative. Speakers from the RECOVER adult, pediatric, and autopsy cohorts provided an overview of the progress to date, what is in the pipeline and the ultimate promise of RECOVER for each of the cohorts. A review of the current state of the science of Long COVID and gaps in knowledge was also discussed.

R3 Seminar Recap: Impacts of SARS-CoV-2 on brain, gut, and metabolism

During the December 12th RECOVER Research Review (R3) Seminar, panelists discussed immune features of Long COVID, the relationship between Long COVID and metabolism (chemical reactions that provide the body with energy), and impact of acute and Long COVID on the brain.

R3 Seminar Recap: Understanding the role of the immune system in PASC

During the November 14th RECOVER Research Review (R3) Seminar, researchers discussed multiple different biological mechanisms likely underlaid PASC manifestations. This seminar explored several prominent mechanisms that were areas of active study, including persistent SARS-CoV-2 viral reservoirs, abnormal immune system activation, and effects on metabolic pathways.

Now Available: Dataset for “Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection”

Authorized researchers may request access to the dataset, which contains more than 3.3 million de-identified data entries and a Data Dictionary.

Changes in the body provide clues for the development of Long COVID

A research team that includes RECOVER researchers found changes in the immune systems of people with Long COVID.

RECOVER-NEURO enrolls first participant in trial

RECOVER-NEURO will enroll 315 people and test several different treatments for Long COVID patients who have difficulty focusing, thinking clearly, and remembering things.

NIH launches long COVID clinical trials through RECOVER Initiative, opening enrollment

Initially, RECOVER will test at least four potential treatments for Long COVID, with test of seven more treatments expected in the coming months.

RECOVER-VITAL enrolls first participant in trial

RECOVER-VITAL will enroll 900 people over the next six months and seek to understand whether taking Paxlovid, an antiviral drug, can improve Long COVID symptoms caused by viral persistence.